Alexandra Gerlach, Associate Editor

The findings showed that pharmacist-led interventions resulted in the greatest systolic blood pressure reductions.

Acetylcholine deficit observed in patients with anorexia nervosa suggest potential targeted treatment options.

Radiotherapy may have applications beyond symptomatic relief when used in combination with immunotherapy.

Use of semaglutide injections may be linked to an increased risk of blindness in patients with diabetes.

Prediction model can accurately predict the risk of nerve damage in patients who received taxane-based chemotherapy.

Consumer-wearable devices can monitor treatment response and provide continuous health data for patients with heart disease and atrial fibrillation.

Increased awareness of women's cardiovascular health and the impact of estrogen fluctuation throughout women’s lives on cardiovascular disease could both boost the economy and improve health outcomes.

Unique gut flora were found in children with autism spectrum disorder (ASD).

Dupilumab may improve disease severity in children with eosinophilic esophagitis (EoE).

Extended treatment with high doses of cisplatin-based chemotherapy is associated with severe and progressive hearing loss.

Early diagnosis and comprehensive treatment may lead to full recovery for patients.

Pulsed field ablation may offer patients an efficacious treatment option with limited damage to surrounding tissues.

Researchers identify significant proteins involved in the growth and survival of malignant multiple myeloma cells.

Palliative care may help reduce symptoms and improve quality-of-life for patients with cardiovascular disease.

Omar Nadeem, MD, discusses positive outcomes associated with GPRC5D-targeted CAR T-cell therapy.

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC).

Chimeric antigen receptor (CAR) T-cell therapy can engineer T cells to target malignant cells in multiple myeloma.

Follow-up data reveal 10-year impact of ibrutinib in treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Perinatal depression increases the risk of cardiovascular disease in women.

Tepylute is a ready-to-dilute, injectable formula that reduces preparation time and enable dosing accuracy.

Antibody drug conjugate TUB-040 demonstrated superior biophysical properties for treating platinum-resistant ovarian cancer.

A report from the Milken Institute highlights the crucial role of pharmacists in advancing food is medicine care.

A biologics license application (BLA) for patritumab deruxtecan receives complete response letter due to inspection findings at third-party manufacturer.

The supplemental new drug application (sNDA) for brexpiprazole is accepted by the FDA for treatment of patients with post-traumatic stress disorder (PTSD).

Adagrasib receives accelerated approval for patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC).

Adopting the Planetary Health Diet may reduce overall risk of chronic disease and premature death.

Study shows that orange peel extract may reduce risk of heart disease and adverse cardiovascular events.

Secondhand exposure to e-cigarette smoke may increase risk of pediatric atopic dermatitis in children.

The FDA approved blinatumomab for treatment of patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Zanubrutinib shows potential in treating patients with treatment-naïve high-risk chronic lymphocytic leukemia and/or small lymphocytic lymphoma with del(17p) and/or TP53 mutation.